{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:07:10Z","timestamp":1784045230069,"version":"3.55.0"},"reference-count":157,"publisher":"Elsevier","isbn-type":[{"value":"9780443345234","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019286","name":"Ajman University","doi-asserted-by":"publisher","award":["2025-IRG-DRG-10"],"award-info":[{"award-number":["2025-IRG-DRG-10"]}],"id":[{"id":"10.13039\/501100019286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apcsb.2026.04.008","type":"book-chapter","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:44:21Z","timestamp":1778247861000},"page":"95-134","source":"Crossref","is-referenced-by-count":0,"title":["Targeting kinases in neurodegenerative diseases and cancer: Structural insights and therapeutic strategies"],"prefix":"10.1016","author":[{"given":"Anas","family":"Shamsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleha","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuzin","family":"Dinislam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.008_bib1","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chemical Society Reviews"},{"issue":"15","key":"10.1016\/bs.apcsb.2026.04.008_bib2","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1523\/JNEUROSCI.4901-05.2006","article-title":"Long-term effects of brief acute stress on cellular signaling and hippocampal LTP","volume":"26","author":"Ahmed","year":"2006","journal-title":"Journal of neuroscience"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.008_bib3","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s00432-021-03669-5","article-title":"Aurora B kinase: a potential drug target for cancer therapy","volume":"147","author":"Ahmed","year":"2021","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib4","first-page":"1","article-title":"Kinase inhibitors: An overview","author":"Ali","year":"2022","journal-title":"Protein Kinase Inhibitors"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijbiomac.2020.06.078","article-title":"Structural and biochemical investigation of MARK4 inhibitory potential of cholic acid: Towards therapeutic implications in neurodegenerative diseases","volume":"161","author":"Anwar","year":"2020","journal-title":"International Journal of Biological Macromolecules"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188568","article-title":"Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy","volume":"1876","author":"Anwar","year":"2021","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: Targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib8","first-page":"0747","article-title":"Advancements in protein kinase inhibitors: From discovery to clinical applications","volume":"8","author":"Baldi","year":"2025","journal-title":"Research; a Journal of Science and its Applications"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib9","series-title":"New kinase-based molecular diagnostic tools for target discovery, live imaging, and drug response profiling in cancer","author":"Baryyan","year":"2024"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-biochem-060815-014659","article-title":"Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction","volume":"85","author":"Bergeron","year":"2016","journal-title":"Annual Review of Biochemistry"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168554","article-title":"Disruption of axonal transport in neurodegeneration","volume":"133","author":"Berth","year":"2023","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku1094","article-title":"Mechismo: Predicting the mechanistic impact of mutations and modifications on molecular interactions","volume":"43","author":"Betts","year":"2015","journal-title":"Nucleic Acids Research"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/jm8010542","article-title":"Kinase domain mutations in cancer: Implications for small molecule drug design strategies","volume":"52","author":"Bikker","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578180","article-title":"Microglia mediated neuroinflammation in neurodegenerative diseases: A review on the cell signaling pathways involved in microglial activation","volume":"383","author":"Biswas","year":"2023","journal-title":"Journal of Neuroimmunology"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib15","first-page":"1399","article-title":"Hallmarks of neurodegenerative disease: A systems pharmacology perspective","volume":"11","author":"Bloomingdale","year":"2022","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"6835","key":"10.1016\/bs.apcsb.2026.04.008_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.008_bib17","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1021\/cr000250y","article-title":"Chemical inhibitors of protein kinases","volume":"101","author":"Bridges","year":"2001","journal-title":"Chemical Reviews"},{"issue":"3-4","key":"10.1016\/bs.apcsb.2026.04.008_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1089\/ars.2006.8.444","article-title":"Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: Relevance to brain aging, neurodegenerative disorders, and longevity","volume":"8","author":"Calabrese","year":"2006","journal-title":"Antioxidants & Redox Signaling"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib19","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1038\/s41467-024-49196-y","article-title":"Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target","volume":"15","author":"Caldi Gomes","year":"2024","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.008_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc3277","article-title":"Spatial regulation of receptor tyrosine kinases in development and cancer","volume":"12","author":"Casaletto","year":"2012","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41420-023-01299-z","article-title":"PRMT5-mediated regulatory arginine methylation of RIPK3","volume":"9","author":"Chauhan","year":"2023","journal-title":"Cell Death Discovery"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib23","first-page":"1","article-title":"Azetidines in medicinal chemistry: Emerging applications and approved drugs","author":"Cheekatla","year":"2026","journal-title":"Future Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib25","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cells8101172","article-title":"Mitogen-activated protein kinases (MAPKs) and cholangiocarcinoma: The missing link","volume":"8","author":"Chen","year":"2019","journal-title":"Cells"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib26","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nrd2999","article-title":"Targeting protein kinases in central nervous system disorders","volume":"8","author":"Chico","year":"2009","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pneurobio.2005.02.004","article-title":"Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease","volume":"75","author":"Chong","year":"2005","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-802208-5.00005-9","article-title":"Biomarker development in targeting cancer epigenetic","author":"Cisarovsky","year":"2016","journal-title":"Drug Discovery in Cancer Epigenetics"},{"issue":"13","key":"10.1016\/bs.apcsb.2026.04.008_bib29","doi-asserted-by":"crossref","first-page":"10809","DOI":"10.3390\/ijms241310809","article-title":"Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and amyotrophic lateral sclerosis","volume":"24","author":"Ciurea","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/bies.10355","article-title":"Chronic activation of ERK and neurodegenerative diseases","volume":"25","author":"Colucci\u2010D\u2032Amato","year":"2003","journal-title":"Bioessays: News and Reviews in Molecular, Cellular and Developmental Biology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib31","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1038\/s41467-023-41890-7","article-title":"An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function","volume":"14","author":"Cuesta-Hern\u00e1ndez","year":"2023","journal-title":"Nature Communications"},{"issue":"34","key":"10.1016\/bs.apcsb.2026.04.008_bib32","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.2174\/138161209789649330","article-title":"Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions","volume":"15","author":"Cuny","year":"2009","journal-title":"Current Pharmaceutical Design"},{"issue":"21","key":"10.1016\/bs.apcsb.2026.04.008_bib33","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.3390\/molecules27217207","article-title":"Potential of therapeutic small molecules in apoptosis regulation in the treatment of neurodegenerative diseases: An updated review","volume":"27","author":"Dailah","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib34","series-title":"Modular protein domains","first-page":"181","article-title":"The eukaryotic protein kinase domain","author":"Dar","year":"2005"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib35","unstructured":"Dhal, A.K., & Ritaparna, P. (2024). An Insight on Protein Kinases and Their Therapeutic Perspective, 131."},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007485","article-title":"Sequence and structure signatures of cancer mutation hotspots in protein kinases","volume":"4","author":"Dixit","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10522-014-9523-2","article-title":"Inverse association between cancer and neurodegenerative disease: Review of the epidemiologic and biological evidence","volume":"15","author":"Driver","year":"2014","journal-title":"Biogerontology"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12013-024-01248-2","article-title":"Oxidative stress, endoplasmic reticulum stress and apoptosis in the pathology of Alzheimer\u2019s disease","volume":"82","author":"Ekundayo","year":"2024","journal-title":"Cell Biochemistry and Biophysics"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib39","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1039\/D5MD00494B","article-title":"Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects","volume":"16","author":"Elgawish","year":"2025","journal-title":"RSC Medicinal Chemistry"},{"issue":"2-3","key":"10.1016\/bs.apcsb.2026.04.008_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0163-7258(02)00180-8","article-title":"Structural aspects of protein kinase control\u2014role of conformational flexibility","volume":"93","author":"Engh","year":"2002","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.855776","article-title":"Pre-clinical studies identifying molecular pathways of neuroinflammation in Parkinson\u2019s disease: A systematic review","volume":"14","author":"Fathi","year":"2022","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib42","doi-asserted-by":"crossref","unstructured":"Ferguson, D.,\u00a0RSci MRSB MRSC. (2025). AI\u2011Driven Integrative Design of ADAMTS Partial Agonists within a Multi\u2011Hallmark Therapeutic Framework for Neurodegenerative Disorders.","DOI":"10.26434\/chemrxiv-2025-4n2nb-v4"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.008_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","article-title":"Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression","volume":"29","author":"Gao","year":"2008","journal-title":"Trends in Immunology"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.008_bib44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/MMBR.00027-06","article-title":"Impact of protein kinase PKR in cell biology: From antiviral to antiproliferative action","volume":"70","author":"Garcia","year":"2006","journal-title":"Microbiology and Molecular Biology Reviews"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.0.CO;2-2","article-title":"ATP site\u2010directed competitive and irreversible inhibitors of protein kinases","volume":"20","author":"Garc\u00eda\u2010Echeverr\u00eda","year":"2000","journal-title":"Medicinal Research Reviews"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-pharmtox-010919-023545","article-title":"Cryo-electron microscopy: Moving beyond X-ray crystal structures for drug receptors and drug development","volume":"60","author":"Garc\u00eda-Nafr\u00eda","year":"2020","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/7355_2020_103","article-title":"Covalent kinase inhibitors: An overview","author":"Gehringer","year":"2020","journal-title":"Proteinkinase Inhibitors"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tibs.2015.08.003","article-title":"Regulation of axonal transport by protein kinases","volume":"40","author":"Gibbs","year":"2015","journal-title":"Trends in Biochemical Sciences"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10555-007-9065-z","article-title":"Hypoxia and adaptive landscapes in the evolution of carcinogenesis","volume":"26","author":"Gillies","year":"2007","journal-title":"Cancer and Metastasis Reviews"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.008_bib50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single-to multi-target drugs in cancer therapy: When aspecificity becomes an advantage","volume":"15","author":"Giordano","year":"2008","journal-title":"Current Medicinal Chemistry"},{"issue":"6a","key":"10.1016\/bs.apcsb.2026.04.008_bib51","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1582-4934.2008.00402.x","article-title":"Neuronal cell death in neurodegenerative diseases: Recurring themes around protein handling","volume":"12","author":"Gorman","year":"2008","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2024.102890","article-title":"Exploring the conformational landscape of protein kinases","volume":"88","author":"Gough","year":"2024","journal-title":"Current Opinion in Structural Biology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/biomedicines14010181","article-title":"Rationally designed dual kinase inhibitors for management of obstructive sleep apnea\u2014A computational study","volume":"14","author":"Gramatikoff","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.sbi.2020.01.010","article-title":"Allosteric drugs and mutations: Chances, challenges, and necessity","volume":"62","author":"Guarnera","year":"2020","journal-title":"Current Opinion in Structural Biology"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib55","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1021\/acs.chemrev.5b00590","article-title":"Protein allostery and conformational dynamics","volume":"116","author":"Guo","year":"2016","journal-title":"Chemical Reviews"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib56","article-title":"Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives","author":"Hassan","year":"2025","journal-title":"Journal of Intelligent Medicine"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib57","article-title":"Targeting signaling pathway networks in several malignant tumors: Progresses and challenges","volume":"12","author":"He","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"22","key":"10.1016\/bs.apcsb.2026.04.008_bib58","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.008_bib59","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nature Reviews. Cancer"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1874609811666180223154436","article-title":"At the crossroads between neurodegeneration and cancer: A review of overlapping biology and its implications","volume":"11","author":"Houck","year":"2018","journal-title":"Current aging science"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrg.2016.87","article-title":"Network biology concepts in complex disease comorbidities","volume":"17","author":"Hu","year":"2016","journal-title":"Nature Reviews. Genetics"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1566-2772(03)00057-4","article-title":"Huntingtin phosphorylation and signaling pathways that regulate toxicity in Huntington\u2019s disease","volume":"3","author":"Humbert","year":"2003","journal-title":"Clinical Neuroscience Research"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib63","series-title":"Evolutionary dynamics of malignancy","author":"Jackson","year":"2023"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583508004745","article-title":"Protein kinase inhibitors: Contributions from structure to clinical compounds","volume":"42","author":"Johnson","year":"2009","journal-title":"Quarterly Reviews of Biophysics"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib65","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Medicinal Chemistry"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fonc.2018.00050","article-title":"Phenotypic plasticity, bet-hedging, and androgen independence in prostate cancer: Role of non-genetic heterogeneity","volume":"8","author":"Jolly","year":"2018","journal-title":"Frontiers in Oncology"},{"issue":"17","key":"10.1016\/bs.apcsb.2026.04.008_bib67","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.neuron.2025.08.015","article-title":"Novel approaches to clinical trial design in cancer neuroscience","volume":"113","author":"Jones","year":"2025","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/bi101379m","article-title":"Controlling the activity of the Tec kinase Itk by mutation of the phenylalanine gatekeeper residue","volume":"50","author":"Joseph","year":"2011","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.008_bib69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.14336\/AD.2019.0923","article-title":"Cell cycle deficits in neurodegenerative disorders: Uncovering molecular mechanisms to drive innovative therapeutic development","volume":"11","author":"Joseph","year":"2020","journal-title":"Aging and Disease"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.008_bib70","doi-asserted-by":"crossref","first-page":"739","DOI":"10.17305\/bb.2024.11537","article-title":"Artificial intelligence driven innovations in biochemistry: A review of emerging research frontiers","volume":"25","author":"Junaid","year":"2025","journal-title":"Biomolecules and Biomedicine"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib71","series-title":"Protein kinases and neurodegenerative diseases","first-page":"5574","author":"Kawahata","year":"2023"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.4103\/1673-5374.300331","article-title":"Functional repertoire of protein kinases and phosphatases in synaptic plasticity and associated neurological disorders","volume":"16","author":"Khan","year":"2021","journal-title":"Neural Regeneration Research"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.04.008_bib73","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.3390\/molecules28124672","article-title":"Small molecule inhibitors as therapeutic agents targeting oncogenic fusion proteins: Current status and clinical","volume":"28","author":"Kong","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib74","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends in Biochemical Sciences"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.008_bib75","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjh.17383","article-title":"Pathogenesis of follicular lymphoma: Genetics to the microenvironment to clinical translation","volume":"194","author":"Kumar","year":"2021","journal-title":"British Journal of Haematology"},{"issue":"1-2","key":"10.1016\/bs.apcsb.2026.04.008_bib76","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.resp.2008.05.017","article-title":"Post-translational modification of proteins during intermittent hypoxia","volume":"164","author":"Kumar","year":"2008","journal-title":"Respiratory Physiology & Neurobiology"},{"issue":"578","key":"10.1016\/bs.apcsb.2026.04.008_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aav3810","article-title":"Tracing the origin and evolution of pseudokinases across the tree of life","volume":"12","author":"Kwon","year":"2019","journal-title":"Science Signaling"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib78","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrg2707","article-title":"Kinase mutations in human disease: interpreting genotype\u2013phenotype relationships","volume":"11","author":"Lahiry","year":"2010","journal-title":"Nature Reviews. Genetics"},{"issue":"23","key":"10.1016\/bs.apcsb.2026.04.008_bib79","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","article-title":"Negative feedback regulation of the ERK1\/2 MAPK pathway","volume":"73","author":"Lake","year":"2016","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib80","article-title":"Context\u2010dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches","volume":"11","author":"Lam","year":"2019","journal-title":"Wiley Interdisciplinary Reviews: Systems Biology and Medicine"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.431","article-title":"Progress in cancer neuroscience","volume":"4","author":"Lan","year":"2023","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbcan.2007.08.001","article-title":"Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors","volume":"1785","author":"Landau","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41418-020-00667-x","article-title":"Ubiquitin signaling in neurodegenerative diseases: An autophagy and proteasome perspective","volume":"28","author":"Le Guerrou\u00e9","year":"2021","journal-title":"Cell Death & Differentiation"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib84","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005918","article-title":"Protein regulation in signal transduction","volume":"8","author":"Lee","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib85","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/ijms25105489","article-title":"Kinase inhibitors and kinase-targeted cancer therapies: Recent advances and future perspectives","volume":"25","author":"Li","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70474","article-title":"Protein kinase C family: Structures, biological functions, diseases, and pharmaceutical interventions","volume":"6","author":"Li","year":"2025","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib87","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.pharmthera.2006.02.006","article-title":"Mitotic kinases: The key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis","volume":"111","author":"Li","year":"2006","journal-title":"Pharmacology & Therapeutics"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.008_bib88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41583-022-00603-7","article-title":"Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases","volume":"23","author":"Li","year":"2022","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib89","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/bs.apcsb.2020.09.005","article-title":"Dual roles of ATP-binding site in protein kinases: Orthosteric inhibition and allosteric regulation","volume":"124","author":"Li","year":"2021","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"issue":"1715","key":"10.1016\/bs.apcsb.2026.04.008_bib90","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0260","article-title":"Glutamatergic synapses are structurally and biochemically complex because of multiple plasticity processes: Long-term potentiation, long-term depression, short-term potentiation and scaling","volume":"372","author":"Lisman","year":"2017","journal-title":"Philosophical Transactions of the Royal Society B: Biological Sciences"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib91","series-title":"Cell Biology-New Insights","article-title":"Cell-cycle alterations in post-mitotic cells and cell death by mitotic catastrophe","author":"Lombardi","year":"2016"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1042\/BST20130250","article-title":"HDX-MS takes centre stage at unravelling kinase dynamics","volume":"42","author":"Lorenzen","year":"2014","journal-title":"Biochemical Society Transactions"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib93","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/acs.accounts.8b00570","article-title":"Allosteric methods and their applications: Facilitating the discovery of allosteric drugs and the investigation of allosteric mechanisms","volume":"52","author":"Lu","year":"2019","journal-title":"Accounts of Chemical Research"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.784098","article-title":"The role of immune cells in post-stroke angiogenesis and neuronal remodeling: The known and the unknown","volume":"12","author":"Ma","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1359600","article-title":"ROS signaling in innate immunity via oxidative protein modifications","volume":"15","author":"Manoharan","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"16","key":"10.1016\/bs.apcsb.2026.04.008_bib96","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3390\/cells11162590","article-title":"Proteostasis deregulation in neurodegeneration and its link with stress granules: Focus on the scaffold and ribosomal protein RACK1","volume":"11","author":"Masi","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1381612822666161006153639","article-title":"Predictive biomarkers for linking disease pathology and drug effect","volume":"23","author":"Mayer","year":"2017","journal-title":"Current Pharmaceutical Design"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.008_bib98","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/ars.2011.4019","article-title":"Mitochondrial quality control and dynamics in Parkinson\u2019s disease","volume":"16","author":"McCoy","year":"2012","journal-title":"Antioxidants & Redox Signaling"},{"issue":"33","key":"10.1016\/bs.apcsb.2026.04.008_bib99","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1200\/JCO.2009.22.9054","article-title":"Personalized cancer therapy with selective kinase inhibitors: An emerging paradigm in medical oncology","volume":"27","author":"McDermott","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BST20220940","article-title":"Allosteric regulation and inhibition of protein kinases","volume":"51","author":"Mingione","year":"2023","journal-title":"Biochemical Society Transactions"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.04.008_bib101","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","article-title":"Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, \u2018DFG-out\u2019inhibitors","volume":"40","author":"Modi","year":"2022","journal-title":"Journal of Biomolecular Structure and Dynamics"},{"issue":"15","key":"10.1016\/bs.apcsb.2026.04.008_bib102","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.3390\/cancers13153819","article-title":"Proteins from the DNA damage response: Regulation, dysfunction, and anticancer strategies","volume":"13","author":"Molinaro","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib103","series-title":"The role of oncogenic KRAS in the immune evasion of non-small cell lung cancer UCL","author":"Mugarza Strobl","year":"2021"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.008_bib104","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1158\/1535-7163.MCT-15-0088","article-title":"Durability of kinase-directed therapies\u2014a network perspective on response and resistance","volume":"14","author":"Murray","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tips.2020.12.004","article-title":"Machine learning for biologics: Opportunities for protein engineering, developability, and formulation","volume":"42","author":"Narayanan","year":"2021","journal-title":"Trends in Pharmacological Sciences"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.008_bib106","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1021\/cr0002801","article-title":"Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions","volume":"101","author":"Newton","year":"2001","journal-title":"Chemical Reviews"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/BJ20091035","article-title":"Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson\u2019s disease","volume":"424","author":"Nichols","year":"2009","journal-title":"Biochemical Journal"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib108","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/cdd.2014.204","article-title":"Autophagy in the physiology and pathology of the central nervous system","volume":"22","author":"Nikoletopoulou","year":"2015","journal-title":"Cell Death & Differentiation"},{"issue":"5665","key":"10.1016\/bs.apcsb.2026.04.008_bib109","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein kinase inhibitors: Insights into drug design from structure","volume":"303","author":"Noble","year":"2004","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib110","series-title":"Characterizing oncogene addiction in alveolar rhabdomyosarcoma to find new combination therapies","author":"Ommer","year":"2018"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib111","first-page":"286","article-title":"Hydrogen-deuterium exchange mass spectrometry: A novel structural biology approach to structure, dynamics and interactions of proteins and their complexes","volume":"10","author":"Ozohanics","year":"2020","journal-title":"Life (Chicago, Ill.: 1978)"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib112","article-title":"Designing\u00a0effective\u00a0lead\u00a0molecules\u00a0against\u00a0solid\u00a0tumors\u00a0with\u00a0inadequate\u00a0treatment\u00a0options,\u00a0the\u00a0efficacy\u00a0problem","author":"Pantsar","year":"2018","journal-title":"Asia-Pacific Journal of Oncology"},{"issue":"18","key":"10.1016\/bs.apcsb.2026.04.008_bib113","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1021\/acs.chemrev.7b00698","article-title":"Redox signaling by reactive electrophiles and oxidants","volume":"118","author":"Parvez","year":"2018","journal-title":"Chemical Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib114","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.3390\/ijms24032272","article-title":"Molecular mechanisms underlying neuroinflammation elicited by occupational injuries and toxicants","volume":"24","author":"Pathak","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/adt.2006.4.185","article-title":"Overcoming the hurdle of fluorescent compounds in kinase screening: A case study","volume":"4","author":"Perrin","year":"2006","journal-title":"Assay and Drug Development Technologies"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib116","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/cells8030260","article-title":"Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer\u2019s disease","volume":"8","author":"Pradeepkiran","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib118","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/ITT.S532291","article-title":"Precision medicine in asthma: The role of biomarkers","author":"Quek","year":"2025","journal-title":"ImmunoTargets and Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib119","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: A review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS Neuroscience"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib120","series-title":"The interplay of Aurora kinase A, EGFR, and SRC pathways in regulating cancer resistance to targeted therapy","author":"Ratushny","year":"2011"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib121","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88210","article-title":"A critical evaluation of protein kinase regulation by activation loop autophosphorylation","volume":"12","author":"Reinhardt","year":"2023","journal-title":"Elife"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib122","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12325-019-01148-5","article-title":"Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: A narrative review","volume":"37","author":"Rekatsina","year":"2020","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib123","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13104-017-2428-9","article-title":"A computational protocol to evaluate the effects of protein mutants in the kinase gatekeeper position on the binding of ATP substrate analogues","volume":"10","author":"Romano","year":"2017","journal-title":"BMC Research Notes"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.008_bib124","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrclinonc.2012.22","article-title":"Drug development and clinical trials\u2014the path to an approved cancer drug","volume":"9","author":"Rubin","year":"2012","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/bies.201600048","article-title":"Diminishing return for mechanistic therapeutics with neurodegenerative disease duration? There may be a point in the course of a neurodegenerative condition where therapeutics targeting disease\u2010causing mechanisms are futile","volume":"38","author":"Rubinsztein","year":"2016","journal-title":"Bioessays: News and Reviews in Molecular, Cellular and Developmental Biology"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbapap.2009.07.018","article-title":"Addiction to protein kinase CK2: A common denominator of diverse cancer cells?","volume":"1804","author":"Ruzzene","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.008_bib127","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4314\/tjpr.v23i7.21","article-title":"An overview of polypharmacology: A multifaceted approach to drug development","volume":"23","author":"Samman","year":"2024","journal-title":"Tropical Journal of Pharmaceutical Research"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Safety"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.14712\/fb2006052030081","article-title":"Protein kinases, their function and implication in cancer and other diseases","volume":"52","author":"Shchemelinin","year":"2006","journal-title":"Folia Biologica"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.008_bib130","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2014.10.051","article-title":"A glimpse of structural biology through X-ray crystallography","volume":"159","author":"Shi","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/cells9010129","article-title":"Mutations that confer drug-resistance, oncogenicity and intrinsic activity on the ERK MAP kinases\u2014current state of the art","volume":"9","author":"Smorodinsky-Atias","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib132","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1023\/A:1007507224529","article-title":"Protein kinases as therapeutic targets","volume":"17","author":"Sridhar","year":"2000","journal-title":"Pharmaceutical Research"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.008_bib133","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity\u2014focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib134","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/pharmaceutics12100948","article-title":"Pharmacokinetic principles and their application to central nervous system tumors","volume":"12","author":"Straehla","year":"2020","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.008_bib135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/PPO.0b013e3181bd0445","article-title":"Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development","volume":"15","author":"Tan","year":"2009","journal-title":"The Cancer Journal"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.008_bib136","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14789450.2015.1042866","article-title":"The role of structural disorder in cell cycle regulation, related clinical proteomics, disease development and drug targeting","volume":"12","author":"Tantos","year":"2015","journal-title":"Expert Review of Proteomics"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib137","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1140\/epjb\/s10051-021-00207-7","article-title":"Tyrosine kinases: Complex molecular systems challenging computational methodologies","volume":"94","author":"Thomas","year":"2021","journal-title":"The European Physical Journal B"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib138","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12014-020-09305-7","article-title":"Clinical proteomics for prostate cancer: Understanding prostate cancer pathology and protein biomarkers for improved disease management","volume":"17","author":"Tonry","year":"2020","journal-title":"Clinical Proteomics"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.008_bib139","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1432-1033.2004.04094.x","article-title":"Unraveling DNA helicases: Motif, structure, mechanism and function","volume":"271","author":"Tuteja","year":"2004","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.cb.10.110194.001343","article-title":"Protein-tyrosine kinases and their signal transduction pathways","volume":"10","author":"Van der Geer","year":"1994","journal-title":"Annual Review of Cell Biology"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib141","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.3390\/ijms23063223","article-title":"Oncogenic pathways in neurodegenerative diseases","volume":"23","author":"Varela","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib142","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.sbi.2021.06.002","article-title":"Making the invisible visible: Toward structural characterization of allosteric states, interaction networks, and allosteric regulatory mechanisms in protein kinases","volume":"71","author":"Verkhivker","year":"2021","journal-title":"Current Opinion in Structural Biology"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1098454","article-title":"Study design challenges and strategies in clinical trials for rare diseases: Lessons learned from pantothenate kinase-associated neurodegeneration","volume":"14","author":"Videnovic","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib144","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"15","key":"10.1016\/bs.apcsb.2026.04.008_bib145","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers15153837","article-title":"Precision medicine: Disease subtyping and tailored treatment","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib146","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","article-title":"Allosteric small-molecule kinase inhibitors","volume":"156","author":"Wu","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib147","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-025-02179-x","article-title":"Protein kinases in neurodegenerative diseases: Current understandings and implications for drug discovery","volume":"10","author":"Wu","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"6513","key":"10.1016\/bs.apcsb.2026.04.008_bib148","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc2754","article-title":"Conformational states dynamically populated by a kinase determine its function","volume":"370","author":"Xie","year":"2020","journal-title":"Science (New York, N. Y.)"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.008_bib149","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/jmbi.1998.1979","article-title":"GlnK, a PII-homologue: Structure reveals ATP binding site and indicates how the T-loops may be involved in molecular recognition","volume":"282","author":"Xu","year":"1998","journal-title":"Journal of Molecular Biology"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.008_bib150","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/ijms19113534","article-title":"Structure and physiological regulation of AMPK","volume":"19","author":"Yan","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib151","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/iub.2253","article-title":"Emerging roles of the \u03b1C\u2010\u03b24 loop in protein kinase structure, function, evolution, and disease","volume":"72","author":"Yeung","year":"2020","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib152","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.sbi.2010.10.001","article-title":"Pseudokinases-remnants of evolution or key allosteric regulators?","volume":"20","author":"Zeqiraj","year":"2010","journal-title":"Current Opinion in Structural Biology"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib153","series-title":"Structural and biophysical regulation of the receptor tyrosine kinases dROS1 and ErbB3","author":"Zhang","year":"2024"},{"key":"10.1016\/bs.apcsb.2026.04.008_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.eswa.2025.126566","article-title":"Systematic prediction of synergistic drug combinations through network-based deep learning framework","volume":"270","author":"Zhang","year":"2025","journal-title":"Expert Systems with Applications"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.008_bib155","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chemical Biology"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.008_bib156","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1517\/17460441.2015.1061991","article-title":"X-ray crystallography over the past decade for novel drug discovery\u2013where are we heading next?","volume":"10","author":"Zheng","year":"2015","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.008_bib157","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: Exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Molecular targets and therapeutic design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162326000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162326000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:36:43Z","timestamp":1784043403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162326000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443345234"],"references-count":157,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2026.04.008","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}